Side-by-side · Research reference

CardiogenvsDSIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED5/46 cited

BHuman-MechanisticAUTO-DRAFTED8/36 cited

Cardiogen

Bioregulator · Cardiac

CardiacTissue target

Gene regulationMechanism

AnimalEvidence level

SQ · Variable protocols

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

01Mechanism of Action

Parameter

Cardiogen

DSIP

Primary target

Cardiovascular cell gene expressionKhavinson 2022

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

Pathway

Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasisKhavinson 2022

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

Downstream effect

Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Feedback intact?

Presumed — peptide bioregulators act via gene regulation, not receptor agonism

—

Origin

Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

Antibody development

—

02Dosage Protocols

Parameter

Cardiogen

DSIP

Standard dose

Variable — typically 10–20 mg per course

No standardised human protocol; animal-derived dosing.

100–200 mcg SQ pre-sleepSchneider 1986

Frequency

Intermittent courses — 10–20 days, repeated periodically

Khavinson-school bioregulators typically dosed as periodic interventions, not continuous.

Once daily, pre-sleep

Evidence basis

Animal models / mechanistic studies

No Phase 1+ human trials in PubMed.

Human-mechanistic + early clinicalSchneider 1986

Route

Subcutaneous injection

—

Duration

10–20 day courses, repeated 2–4× per year

Russian geriatric protocols; unclear extrapolation to general populations.

8–12 weeks per cycle

Lower / starter dose

—

50 mcg pre-sleep

Reconstitution

—

Bacteriostatic water

Timing

—

30–60 min pre-sleep

Half-life

—

Short plasma; CNS effects last hours

04Side Effects & Safety

Parameter

Cardiogen

DSIP

Injection site reactions

Mild erythema, induration (presumed)

—

Systemic adverse events

No documented serious AEs in available literature

Very limited safety data; no rigorous pharmacovigilance.

—

Immunogenicity

Unknown — no antibody development studies published

—

Long-term safety

Unknown — no extended human trials indexed in PubMed

Limited modern RCT data

Injection site reaction

—

Mild irritation

Drowsiness

—

Expected effect (intentional)

Vivid dreams

—

Anecdotally reported

Pregnancy / OB

—

Avoid

Absolute Contraindications

Cardiogen

·Active malignancy (theoretical peptide growth factor concern)
·Hypersensitivity to peptide components

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

Relative Contraindications

Cardiogen

·Acute cardiac events (no safety data in acute MI, unstable angina)
·Pregnancy / lactation (no reproductive toxicity data)

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

05Administration Protocol

Parameter

Cardiogen

DSIP

1. Reconstitution

Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.

Add 1–2 mL bacteriostatic water to vial.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.

SQ — abdomen. Rotate sites.

3. Timing

Variable — often evening injection. No established circadian preference.

30–60 min pre-sleep.

4. Storage

Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

5. Needle

27–30G insulin syringe, 45° angle for subcutaneous administration.

29–31G insulin syringe.

06Stack Synergy

Cardiogen

+ Thymalin

Moderate

View Thymalin →

Khavinson-school multi-organ bioregulator approach: thymalin (thymic peptide) addresses immune senescence while cardiogen targets cardiac tissue. Combined use in geriatric populations demonstrated normalisation of cardiovascular, endocrine, and immune parameters with reduced mortality over 6–8 years of observation.

Cardiogen: 10–20 mg SQ · 10–20 day course
Thymalin: 10–30 mg IM · concurrent or sequential courses
Frequency: 2–4 courses per year
Primary benefit: Multi-system aging mitigation, cardiovascular and immune homeostasis

DSIP

— no documented stacks